Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2020

11.12.2019 | Guidelines

[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0

verfasst von: Cristina Nanni, Lucia Zanoni, Tore Bach-Gansmo, Heikki Minn, Frode Willoch, Trond Velde Bogsrud, Ephraim Parent Edward, Bital Savir-Baruch, Eugene Teoh, Fenton Ingram, Stefano Fanti, David M. Schuster

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

The aim of this guideline is to provide standards for the recommendation, performance, interpretation, and reporting of [18F]Fluciclovine PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of [18F]Fluciclovine PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
Literatur
1.
Savir-Baruch B, Zanoni L, Schuster DM. Imaging of prostate cancer using fluciclovine. Urol Clin North Am. 2018;45:489–502.PubMed
2.
Washburn LC, Sun TT, Byrd B, Hayes RL, Butler TA. 1-aminocyclobutane[11C] carboxylic acid, a potential tumor-seeking agent. J Nucl Med. 1979;20:1055–61.PubMed
3.
ShoupTM OJ, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–8.
4.
Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu W, et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48:46–55.PubMed
5.
Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63.PubMed
6.
Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. PractRadiatOncol. 2018;8:28–39.
7.
Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011;52:822–9.PubMed
8.
Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y. Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2012;39:109–19.PubMed
9.
10.
Wang Q, Hardie R-A, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236:278–89.PubMedPubMedCentral
11.
Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, et al. Up-regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells. J Urol. 2016;195:1588–97.PubMed
12.
Otsuki H, Kimura T, Yamaga T, Kosaka T, Suehiro J, Sakurai H. Prostate cancer cells in different androgen receptor status employ different leucine transporters. Prostate. 2017;77:222–33.PubMed
13.
Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254–66.PubMed
14.
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136:521–34.PubMedPubMedCentral
15.
Goberdhan DCI, Wilson C, Harris AL. Amino acid sensing by mTORC1: intracellular transporters mark the spot. Cell Metab. 2016;23:580–9.PubMedPubMedCentral
16.
Okudaira H, Oka S, Ono M, Nakanishi T, Schuster DM, Kobayashi M, et al. Accumulation of of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression on amino acid transporters. Mol Imaging Biol. 2014;16:756–64.PubMedPubMedCentral
17.
Ono M, Oka S, Okudaira H, Nakanishi T, Mizokami A, Kobayashi M, et al. [14C]fluciclovine (alias anti-[14C]FACBC) uptake and ASCT2 expression in castration resistant prostate cancer cells. Nucl Med Biol. 2015;42:887–92.PubMed
18.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDGPET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.PubMed
19.
Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.PubMed
20.
Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–74.PubMed
21.
Akin-Akintayo OO, Jani AB, Odewole O, et al. Change in salvage radiotherapy management based on guidance with FACBC (fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer. Clin Nucl Med. 2017;42:e22–8.PubMedPubMedCentral
22.
Kairemo K, Rasulova N, Partanen K, Joensuu T. Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients. Biomed Res Int. 2014;2014:305182.PubMedPubMedCentral
23.
Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of [18F]Fluciclovine positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197:676–83.PubMed
24.
Schuster DM, Nieh PT, Jani AB, et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2014;191:1446–53.PubMed
25.
Nanni C, Zanoni L, Pultrone C, et al. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016;43:1601–10.PubMed
26.
Oka S, Kanagawa M, Doi Y, Schuster DM, Goodman MM, Yoshimura H. PET tracer 18F-Fluciclovine can detect histologically proven bone metastatic lesions: a preclinical study in rat osteolytic and osteoblastic bone metastasis models. Theranostics. 2017;7:2048–64.PubMedPubMedCentral
27.
28.
Geinitz H, et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2012;82(5):1930–7.PubMed
29.
Michalski JM, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–8.PubMed
30.
Andriole GL, et al. The impact of positron emission Tomography with (18)F-Fluciclovine on the management of patients with biochemical recurrence of prostate cancer: results from the LOCATE Trial. J Urol. 2018.
31.
32.
33.
Sörensen J, Owenius R, Lax M, Johansson S. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(3):394–402.PubMed
34.
McParland BJ, Wall A, Johansson S, Sørensen J. The clinical safety, biodistribution and internal radiation dosimetry of [18F]fluciclovine in healthy adult volunteers. Eur J Nucl Med Mol Imaging. 2013;40(8):1256–64.PubMed
35.
36.
37.
Zanoni L, Bossert I, Matti A, Schiavina R, Pultrone C, Fanti S, et al. A review discussing fluciclovine ((18)F) PET/CT imaging in the detection of recurrent prostate cancer. Future Oncol. 2018;14(11):1101–15.PubMed
38.
Parent EE, Schuster DM. Update on (18)F-Fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018;59(5):733–9.PubMedPubMedCentral
39.
Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55(12):1986–92.PubMedPubMedCentral
40.
Schuster DM, Taleghani PA, Nieh PT, et al. Characterization of primary prostate carcinoma by anti-1-amino-2-[18F]-fluorocyclobutane-1-carboxylic acid (anti-3- [18F] FACBC) uptake. Am J Nucl Med Mol Imaging. 2013;3:85–96.PubMedPubMedCentral
41.
Ulaner GA, Schuster DM. Amino acid metabolism as a target for breast cancer imaging. PET Clinics. 2018;13(3):437–44.PubMedPubMedCentral
42.
Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, et al. [(18)F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Res. 2018;8(1):67.PubMedPubMedCentral
43.
Sannananja B, Shah HU, Behnia F. 18F-Fluciclovine uptake by an incidentally detected hepatocellular carcinoma in a case of biochemically recurrent prostate cancer. Clin Nucl Med. 2018;43(9):695–6.PubMed
44.
Amzat R, Taleghani P, Miller DL, et al. Pilot study of the utility of the syntheticPET amino-acid radiotracer anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. Mol Imaging Biol. 2013;15:633–43.PubMed
45.
Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11(6):434–8.PubMed
46.
Schuster DM, Votaw JR, Halkar RK, et al. Uptake of the synthetic PET amino acid radiotracer 1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) within primary and metastatic brain cancer compared with 18F-fluorodeoxyglucose (18F-FDG) [abstract]. J Nucl Med. 2003;44(suppl):167P.
47.
Nguyen QB, Amato R, Riascos R, Ballester L, Tandon N, Blanco A, et al. Fluciclovine, Anti-1-amino-3-[(18)F]-fluorocyclobutane-1-carboxylic acid: a novel radiotracer for meningioma. World Neurosurg. 2018.
48.
Husband JE, Padhani AR. Radiologists RCo. Recommendations for cross-sectional imaging in cancer management. London: Royal College of Radiologists; 2006.
49.
Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med. 2007;48(6):1017–20.PubMed
Metadaten
Titel
[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0
verfasst von
Cristina Nanni
Lucia Zanoni
Tore Bach-Gansmo
Heikki Minn
Frode Willoch
Trond Velde Bogsrud
Ephraim Parent Edward
Bital Savir-Baruch
Eugene Teoh
Fenton Ingram
Stefano Fanti
David M. Schuster
Publikationsdatum
11.12.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04614-y

Weitere Artikel der Ausgabe 3/2020

European Journal of Nuclear Medicine and Molecular Imaging 3/2020 Zur Ausgabe

Original Article

The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Correction

Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Image of the Month

Isolated involvement of thyroid gland by IgG4-related disease revealed by 18F-FDG PET/CT

Original Article

68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol

Image of the Month

Extranodal involvement of multiple organs in diffuse large B cell lymphoma detected on 18F-FDG PET/CT

Short Communication

Planar scan vs. SPECT/low-dose CT for estimating split renal function by 99mTc-DMSA scintigraphy in children